PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells
Immunology & Cell Biology · 2025
DOI: 10.1111/imcb.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology & Cell Biology, 2025. Verfasst von Julia Bier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. Hauptthemen laut MEDLINE: Lymphocyte Activation, B-Lymphocytes, Class I Phosphatidylinositol 3-Kinases, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, American Association of Immunologists.
Abstract (Originalsprache)
Activated PI3K delta syndrome 1 (APDS1) is caused by a heterozygous germline gain‐of‐function (GOF) variant in PIK3CD , which encodes the p110δ catalytic subunit of phosphoinositide 3‐kinase (PI3K). APDS1 patients display a broad range of clinical manifestations and perturbations in cellular phenotype. One of the most striking features is the dysregulation of the T‐cell compartment, characterized by an increase in memory T cells, including Tfh cells, and a concomitant decrease in naïve T cells. We have previously shown that many of these changes in T‐cell populations were T‐cell extrinsic and were also induced in WT T cells that developed in the presence of PI3K GOF cells. Here we dissected the drivers of dysregulated T‐cell activation using a mouse model of APDS1. This revealed that PI3K GOF macrophages and DCs made little contribution to the aberrant T‐cell activation. Instead, PI3K GOF T cells were able to drive the loss of WT naïve CD4 + T cells, while dysregulated PI3K GOF B cells mediated an increase in Tfh cells. Surprisingly, despite previous reports of increased PI3K signalling driving dysregulated inflammatory Tregs, we saw no evidence for Pik3cd GOF Tregs acquiring an inflammatory phenotype and driving T‐cell activation. These studies provide new insights into the role of PI3K in immune cells and how increased PI3K can drive T‐ and B‐cell dysregulation and contribute to the phenotype of APDS1 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
- St Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
- Kirby Institute, Faculty of Medicine and Health, UNSW Sydney, Kensington, NSW, Australia.
ORCID-Profile: Elissa K Deenick
Förderung
- National Health and Medical Research Council
- American Association of Immunologists
Zitieren
APA
Bier, J., Lau, A., Jackson, K. J., Ruiz-Diaz, S., Peters, T. J., Brink, R., Tangye, S. G., & Deenick, E. K. (2025). PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells. Immunology & Cell Biology. https://doi.org/10.1111/imcb.70058
Vancouver
Bier J, Lau A, Jackson KJ, Ruiz-Diaz S, Peters TJ, Brink R, et al. PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells. Immunology & Cell Biology. 2025. doi:10.1111/imcb.70058
BibTeX
@article{Bier2025,
author = {Bier, Julia and Lau, Anthony and Jackson, Katherine Jl and Ruiz-Diaz, Stephanie and Peters, Timothy J and Brink, Robert and Tangye, Stuart G and Deenick, Elissa K},
title = {PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells},
journal = {Immunology & Cell Biology},
year = {2025},
doi = {10.1111/imcb.70058}
}
EUVIMED